Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.62 |
| ▸ | TFPI | P10646 | 4/20 | 0.62 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.62 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | KDM5A | P29375 | 1/20 | 0.58 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 2/20 | 0.58 |
| ▸ | NPY4R | P50391 | 2/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.57 |
| ▸ | CALCR | P30988 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335630 | 0.97 | NMUR2 (0.64) | CXCR4TFPINMUR2NMUR1EPHA2 | |
| SCHEMBL31012332 | 0.95 | TFPI (0.63) | CXCR4TFPINMUR2NMUR1NPY2R | |
| SCHEMBL31182515 | 0.90 | TFPI (0.68) | CXCR4TFPINMUR2NMUR1KDM1A | |
| SCHEMBL31182847 | 0.90 | TFPI (0.62) | CXCR4TFPINMUR2NMUR1KDM1A | |
| SCHEMBL30327447 | 0.89 | RAMP3 (0.64) | TFPINMUR2NMUR1KDM1ANPY2R | |
| SCHEMBL30335722 | 0.89 | TFPI (0.64) | TFPINMUR2NMUR1EPHA2NPY2R | |
| SCHEMBL30335928 | 0.89 | EPHA2 (0.68) | TFPINMUR2NMUR1EPHA2NPY2R | |
| SCHEMBL32670411 | 0.89 | EPHA2 (0.68) | TFPINMUR2NMUR1EPHA2NPY2R | |
| SCHEMBL30327403 | 0.89 | EPHA2 (0.68) | TFPINMUR2NMUR1EPHA2NPY2R | |
| SCHEMBL31182912 | 0.89 | NPY2R (0.66) | TFPINMUR2NMUR1NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034197-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | BETAVIVE LTD. (IL) | 2026-02-05 | — | — | US | disclosed |
| US-12447198-B2 | Peptides and fragments for treating diabetes and associated metabolic diseases | BETAVIVE LTD. (IL) | 2025-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447198-B2 | Peptides and fragments for treating diabetes and associated metabolic diseases | IAPP, IGFBP2, IGFBP1 | CXCR4 3580/4885TFPI 1143/4885NMUR2 966/4885 |
| US-20260034197-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | IAPP, GLP1R, IGF1R | CXCR4 2479/4885TFPI 932/4885NMUR2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.